10058-F4 Catalog No.:M8326-2 1007/s40265-019-01181-2

1007/s40265-019-01181-2

1093/jxb/erx483

(2009) Nature Chem Biol

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models

10058-F4 Catalog No.:M8326-2 1007/s40265-019-01181-210058 F4 is a potent and selective c Myc inhibitor, which markedly increases valproic acid induced cell death in Jurkat and CCRF CEM T lymphoblastic leukemia cells. 10058 F4 inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. 10058 F4 induces cell cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Product information CAS